Welcome to our dedicated page for UNITED THERAPEUTICS SEC filings (Ticker: UTHR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
United Therapeutics Corporation filings document an operating biotechnology company with Nasdaq-listed common stock and a public benefit corporation structure. Recent 8-K reports cover quarterly and annual operating results, business updates, clinical-study announcements for Tyvaso and ralinepag, and capital actions such as share repurchase programs and accelerated share repurchase agreements.
Proxy materials describe board elections, director changes, executive compensation, shareholder voting matters and governance practices. The company’s formal disclosures also address its treprostinil-centered pulmonary arterial hypertension business, development programs in pulmonary and transplant-related medicine, and common-stock capital structure.
UNITED THERAPEUTICS Corp CFO and Treasurer James Edgemond exercised stock options and sold shares in a planned transaction. On April 27, 2026, he exercised 10,000 stock options at $135.42 per share and sold 10,000 common shares in multiple open-market trades at weighted-average prices around $565–$572, under a Rule 10b5-1 trading plan entered into on October 31, 2025. After these transactions, he directly holds 18,876 common shares and 52,500 stock options.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine Rothblatt reported an option exercise and related share sales. On April 24, 2026, she exercised stock options covering 9,500 shares of common stock at an exercise price of $146.03 per share and sold 9,500 shares in multiple open‑market transactions at prices generally around the mid‑$560s per share. These transactions were carried out under a pre‑arranged Rule 10b5‑1 trading plan adopted on November 7, 2025. Following the trades, she directly holds 40,513 shares of common stock and also has substantial indirect holdings through various family trusts. The trading plan remains in place until the earlier of the exercise of up to 1,734,410 stock options, all expiring on March 17, 2027, or December 31, 2026.
United Therapeutics CFO and Treasurer James Edgemond exercised stock options to acquire 10,000 shares of common stock at a strike price of $135.42 per share, then sold 10,000 shares in open-market trades on April 22–23, 2026 under a Rule 10b5-1 trading plan.
Sale prices for the common stock ranged around the mid-$570s per share across multiple trades. Following these transactions, he directly holds 18,876 shares of United Therapeutics common stock.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine Rothblatt reported an exercise of stock options and related share sales. She exercised stock options for 9,500 shares of common stock at a conversion price of $146.03 per share and sold 9,500 shares in multiple open-market transactions at weighted average prices in the mid-$570 range, all under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. Following these transactions, she holds 50,013 shares of common stock directly and continues to hold significant indirect positions through family trusts and her spouse, including 324,443 and 258,117 shares in two family trusts. The Rule 10b5-1 plan remains in place until the earlier of the exercise of 1,734,410 stock options expiring on March 17, 2027 or December 31, 2026.
UNITED THERAPEUTICS Corp director Christopher Patusky exercised and sold company stock under a pre-set plan. He exercised stock options for 2,910 shares of common stock at $101.80 per share and, on the same day, sold 2,910 shares at $569.00 per share in an open-market transaction.
The filing states these transactions were carried out under a Rule 10b5-1 trading plan entered into on December 18, 2025. After the sale, he held 1,490 shares directly and 1,100 shares indirectly through a trust, and the exercised stock option covering 2,910 shares was fully used.
Christopher Patusky filed a Form 144 to sell 2,910 shares via stock option exercise on 04/24/2026.
The notice lists the sale method as a Stock Option Exercise through Morgan Stanley Smith Barney LLC on 04/24/2026. The excerpt also reports a prior sale of 1,000 shares on 04/17/2026 for $578,880.00.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine Rothblatt reported exercising stock options and selling resulting shares of common stock under a pre-arranged Rule 10b5-1 trading plan. The plan, adopted on November 7, 2025, continues until either 1,734,410 options expiring on March 17, 2027 are exercised or until December 31, 2026.
Rothblatt exercised 9,500 stock options at $146.03 per share, acquiring the same number of common shares. On the same date, she executed multiple open-market sales totaling 9,500 common shares at weighted average prices generally between the high $572 and $580 per-share range.
Following these transactions, Rothblatt directly holds 40,513 shares of common stock, with additional shares held indirectly through various family trusts and by her spouse as described in the filing. The open-market sales and option exercise form part of the ongoing 10b5-1 trading plan rather than discretionary, one-off trades.
United Therapeutics Chairperson and CEO Martine A. Rothblatt reported an exercise-and-sell transaction in company common stock. On April 21, 2026, she exercised stock options to acquire 9,500 shares at an exercise price of $146.03 per share and sold the same 9,500 shares in multiple open-market trades at prices generally between the mid-$560s and mid-$570s per share.
The filing states these transactions were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which will continue until the earlier of the exercise of 1,734,410 stock options expiring on March 17, 2027 or December 31, 2026. Following the trades, Rothblatt directly holds 49,854 shares and also has indirect ownership through family trusts and spouse accounts, including trust positions such as 324,443 shares of common stock.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine Rothblatt reported an option exercise and related share sales. On April 20, 2026, she exercised 9,500 stock options at an exercise price of $146.03 per share and sold 9,500 shares of common stock in multiple open-market transactions.
The sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, with trade prices generally in the low-to-high $570s per share. After these transactions, she directly holds 40,513 common shares and also has additional indirect holdings through family trusts and her spouse. The 10b5-1 plan contemplates the exercise of up to 1,734,410 stock options that expire on March 17, 2027, or will terminate earlier on December 31, 2026.
UNITED THERAPEUTICS Corp CFO and Treasurer James Edgemond reported an exercise-and-sell transaction in company stock. On April 20, 2026, he exercised 10,000 stock options at $135.42 per share to acquire common stock, then sold 10,000 shares in open‑market trades at prices ranging from about $571.79 to $585.80. The filing shows he now directly holds 18,876 shares of common stock. The transactions were executed under a pre‑arranged Rule 10b5-1 trading plan.